Answers are grounded in this paper and cite their sources.
Purpose of Review Long-acting and extended-release (LA/ER) technologies are expanding options for HIV prevention and treatment, but their population impact will depend on whether products and delivery models align with the priorities and constraints of intended users and providers. We reviewed how stated choice methods have been designed, analyzed, and used to generate implementation-relevant evidence for LA/ER technologies. Recent Findings Fifty peer-reviewed studies published from 2020 to 2026 met inclusion criteria. Most examined HIV prevention (74%), enrolled end-users only (92%), and used discrete choice experiments or related variants (86%). Stakeholder-informed attribute sources were reported in 94%, but only 40% described dedicated, study-specific qualitative or advisory processes. Preference heterogeneity (94%), service-delivery attributes (80%), and structural access barriers (94%) were common. Only 22% included a respondent-specific status-quo comparator, 60% reported comprehension testing, and 4% achieved moderate-to-high representativeness. Although 84% examined pipeline-aligned attributes, reporting did not establish whether those attributes remained modifiable at the relevant product-lifecycle stage. Only four studies included providers, and treatment-preference research was concentrated in high-income settings. Summary Methodological sophistication does not ensure translational utility. Stated choice studies should align their attributes, sampling, and choice architecture with the decision-maker, the product’s lifecycle stage, and the decisions still open to change. As products mature, research should prioritize actionable delivery, access, and health-system decisions and validate preferences against product experience and observed behavior.
No takes yet. Share an insight, caveat, or question.
Bauermeister et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: